Ader, 299 patient HCQ late treatment RCT: 15% higher mortality [p=0.7] and 24% improved viral clearance [p=0.68] https://c19p.org/discovery
copied to clipboard
An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19 - Final results from the DisCoVeRy trial
et al., medRxiv, doi:10.1101/2022.02.16.22271064 (Preprint)
Early terminated very late stage (95% on oxygen at baseline) DISCOVERY trial. 4% more patients were on ventilation at baseline in the HCQ group. This preprint presents more recent results than the earlier journal article.
|
risk of death, 15.3% higher, RR 1.15, p = 0.70, treatment 11 of 150 (7.3%), control 13 of 149 (8.7%), adjusted per study, odds ratio converted to relative risk, day 90.
|
|
risk of death, 10.1% lower, RR 0.90, p = 0.75, treatment 15 of 150 (10.0%), control 13 of 149 (8.7%), adjusted per study, odds ratio converted to relative risk, day 28.
|
|
risk of no viral clearance, 23.8% lower, RR 0.76, p = 0.68, treatment 4 of 83 (4.8%), control 5 of 81 (6.2%), NNT 74, odds ratio converted to relative risk, Table S2, day 29.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
very late stage, >50% on oxygen/ventilation at baseline.
Ader et al., 10/6/2020, Randomized Controlled Trial, multiple countries, multiple regions, preprint, baseline oxygen required 95.4%, 59 authors, study period 22 March, 2020 - 29 June, 2020, average treatment delay 9.0 days.
Contact:
florence.ader@chu-lyon.fr.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.